Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition
|
|
- Magdalen Baker
- 5 years ago
- Views:
Transcription
1 Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition Presented by Cat Dang, D.O Medical Director - Insightful Minds, Inc.
2 Objectives Evaluation process Pharmacology options for ADHD: Stimulants Non-stimulants Pharmacology options for ADHD with co-existing psychiatric conditions: ODD/CD Anxiety Depression Bipolar Learning Disabilities
3 Common Statements I hate movies. I can t sit there for more than 20 minutes. My mind is on something else. I m the class clown. My friends used to call me Monkey. I can t remember to do anything. I m the post-it note queen. I hate reading. By the time I finish the paragraph, I can t remember what the first sentence was about. I always misplace things. I lost two wallets this week.
4 Background Attention Deficit Hyperactivity Disorder (ADHD or ADD)
5 Epidemiology of ADHD Affects 5 to 7 % of prepubertal elementary school children As of 2015 it is estimated to affect about 51.1 million people globally More prevalent in boys than in girls (up to 9:1) Symptoms of ADHD are often present by age 3 years, but the diagnosis is generally not made until the child is in a structured school setting
6 Evaluation Considerations Examination / Confirmation The continuous performance task helps to confirm inattention and impulsivity (TOVA, IVA) Brain mapping (QEEG, SPECT Scan) Rating Scales: Connors, Vanderbilt, Adult ADHD Rating Scale Differential Diagnosis Vision Deficits Hearing Deficits Learning Disabilities Developmental Delays Neurological Abnormalities (absence seizure) Endocrine Disorders: hypothyroidism, anemia, lead poisoning Sleep Disorders: obstructive sleep apnea, narcolepsy, periodic limb movement disorders
7 Course and Prognosis Remission is unlikely before the age of 12 60% - 80% persist into adolescent years When remission does occur, it is usually between the ages of 12 and 20 Most patients with the disorder undergo partial remission but are vulnerable to antisocial behavior, substance use disorders, and mood disorders In about 15 to 20 % of cases, symptoms persist into adulthood
8 At Risk Outcomes Poor academic performance Low self esteem Poor social and interpersonal relationships High risk for injuries, MVA High rates of substance abuse Employment difficulties High risk for teen pregnancy, incarcerations
9 Treatment Options Attention Deficit Hyperactivity Disorder (ADHD or ADD)
10 Medication Treatment Options Methylphenidate class FDA approved for children 6 years old and older Mechanism of Action: reduce the breakdown of dopamine and norepinephrine in prefrontal cortex Dexmethylphenidate (Focalin) D-Isomer of methylphenidate
11 Medication Treatment Options Methylphenidate class: Long acting formulations Aptensio XR (extended release capsule) Contempla XR ODT(extended release oral disintegrating tablet )
12 Medication Treatment Options Amphetamine Salts (Adderall) FDA approved for children 3 years old and older Mechanism of Action: reduces breakdown of dopamine and norepinephrine in prefrontal cortex increases release of dopamine and norepinephrine in prefrontal cortex Dextroamphetamine (Dexedrine) D-Isomer of Amphetamine Salt Milder efficacy Milder side effects
13 Medication Treatment Options Other short-acting variants: Evekeo (amphetamine derivative tablet) Adzenys XR ODT (amphetamine XR oral-disintegrating tablet) Dyanavel XR (amphetamine extended release oral suspension) Zenzedi (dextroamphetamine tablet)
14 Medication Treatment Options Long-acting Variants: Mydayis (amphetamine extended release capsule)
15 Efficacy of Stimulants MTA study (Multimodal Treatment of ADHD) in 1999 Largest study involving 579 children with ADHD ages 7 to 9.9 years old over 14-month treatment 4 study groups: Medication management: 74% on methylphenidate; 10% on dextroamphetamine Behavioral Treatment: parent training, child-focused treatment, school intervention Combined treatment: medication and behavioral management Community Care: parents were given a list of community mental health resources and made whatever treatment arrangements they preferred
16 Efficacy of Stimulants Medication management, and medication with behavioral treatment were the most effective For many children with combined ADHD, medication alone is likely to be effective when care is taken to determine the optimal medication/dose for each child, and when ongoing effectiveness of medication is carefully monitored Intensive and well-conducted behavioral treatment can also be an effective option for treating children with ADHD, but can be hard for parents to implement Children treated by community physicians may be routinely undermedicated Children treated by community physicians are often put on nonstimulant medications and/or combinations of medications that are not necessary 10% of children were on multiple medications More than 16 % were treated with an antidepressant
17 Efficacy of Long-acting Stimulants Daytrana patch: 12-month trial on children with ADHD ages 6-12 years old Side effects: mild loss of appetite, headache 80% effective, without clinically significant change in growth Suggestive use for patients with substance abuse potential Vyvanse: 11-month trial on children with ADHD ages 6-12 years old More consistent plasma level of medication Effective and well tolerated without serious side effects Suggestive use for patients with substance abuse potential
18 Common Side Effects of Stimulants Common Side Effects of Stimulants Headache Stomachache Nausea Decreased appetite Insomnia Irritability Rebound symptoms
19 Serious Side Effects of Stimulants Motor tics: can transiently occur in 15-30% of children taking stimulants Growth suppression: Past studies suggested that "long-term use of the drugs could stunt children's growth. More recent studies suggest that children eventually do reach normal height and weight. Treated children with ADHD tend to grow at a slower rate but catch up during adolescence and adulthood. Drug holidays Psychosis: visual hallucinations, paranoia Cardiovascular side effects: cardiac arrhythmia, sudden death in children with underlying heart problems
20 Medication Treatment Options Strattera (Atomoxetine) Non-stimulant Increases norepinephrine level Less rebound, less insomnia Less abuse potential Takes 3-7 weeks for max effect Some side effects: headache, sedation, irritability, mania, black box warning for suicidal thinking, liver enzyme abnormality
21 Medication Treatment Options Adrenergic Agents Adrenergic Agents: Clonidine and Guanfacine, Intuniv, Kapvay Effective for hyperactive symptoms Less effective for inattention symptoms Guanfacine: 30% improvement for inattention Some side effects: sedation, hypotension, rebound hypertension Antidepressants Antidepressants: Wellbutrin Not indicated in children Increases levels of dopamine and norepinephrine Some side effects: lower seizure threshold, weight loss or decreased appetite, dry mouth, black box warning for suicidal thinking
22 Medication Treatment Options Other Medications The following medications are not FDA approved at this time: Effexor Cymbalta Tricyclic antidepressants: Amitriptyline, Desipramine, Imipramine, Nortriptyline Provigil
23 Medication Treatment Options Genetic Testing: result for a teenage girl
24 Medication Treatment Options Genetic Testing: result for a 30 year old female
25 Monitoring Medication Treatment Physical Exam Blood pressure Pulse Weight Height EKG Feedback from teachers about school performance Feedback from family members TOVA/IVA test while on medication
26 Special Considerations ADHD and Comorbid Psychiatric Conditions
27 ADHD and Comorbid Psychiatric Conditions» Illustration from Joseph Biederman and Stephen Faraone, Harvard Mahoney Neuroscience Institute Letter, Winter 1996 Volume 5 Number 1
28 ADHD and ODD/CD Most common co-morbid disorder is Oppositional Defiant Disorder (ODD) 54-57% of ADHD children get diagnosed with ODD by 7 years of age ODD is precursor for Conduct Disorder (CD) CD in children: 20-50% CD in adolescents: 44-50% CD in adulthood: up to 26%
29 Treatment: ADHD and ODD/CD Stimulants: preferably long-acting forms to avoid abuse Daytrana patch Concerta Vyvanse Alpha-agonists: Clonidine, Kapvay, Clonidine transdermal patch Tenex, Intuniv Mood Stabilizers Atypical Antipsychotics: Risperdal, Abilify, Zyprexa, Seroquel Anticonvulsants: Depakote, Tegretol, Trileptal Lithium
30 Treatment: ADHD and Anxiety Co-existing Anxiety: up to 25% Strattera Antidepressants: Effexor, Pristiq, Cymbalta Combination of Stimulants and Anxiolytic Medications Be aware stimulants may increase anxiety
31 Treatment: ADHD and Depression Co-existing Depression: 26% in children, 14% in adulthood Wellbutrin Antidepressants: Effexor, Pristiq, Cymbalta, etc Combination of Stimulants and Antidepressants
32 Treatment: ADHD and Bipolar Disorder Co-existing Bipolar: 10-20% Combination of Alpha-Agonists and Mood stabilizers Combination of Stimulants and Mood Stabilizers Monitor side effects related to stimulants: irritability, insomnia, psychosis
33 ADHD and Tic disorders Childhood motor tic disorder: 18% By mid-adolescent years: 2% By adulthood: less than 1 % Tourrette s Disorder (motor and vocal tics): less than 0.4% Treatment: alpha-agonist If severe: add atypical antipsychotics (Geodon, Abilify, Risperdal)
34 ADHD and Learning Disabilities 19-26% have one learning disability Reading disorders: 16-39% Spelling disorders: 24-27% Math Disorders: 13-33% Speech and language disorders: 30% Treatment: Psycho-education testing to determine area of deficits, IEP, 504 Accommodations, Behavioral Intervention
35 Psychosocial Interventions and Other Treatment Options Social skills groups: increase self-esteem Training for parents: positive reinforcement, setting routines and limits. Behavioral interventions (organizational skills): ADD Coaching, physical activities Nutrition: omega-3 fatty acid supplements, reduced sugar consumption, reduced caffeine consumption Neurofeedback Individualized Education Program: 504 accommodations Colleges can provide accommodation through Disability Office Career coach
36 References Sadock B, Sadock V. Kaplan & Sadock s Synopsis of Psychiatry, Ninth Edition. Lippincott Williams & Wilkins 2003; 43: American Psychiatric Association: Diagnostic Criteria from DSM-IV-TR. Washington D.C. 2000: Donnelly & Sons Company. WebMD, LLC. Web Oct [ American Academy of Pediatrics. Web. Oct [ Wikipedia: The Free Encyclopedia. Wikimedia Foundation, Inc. Web. Oct [ Medscape. WebMD, LLC. Web. Sept [ MentalHelp.net. CenterSite, LLC. Web. Sept [ Center for Disease Control. Web. Sept [ Psychiatric Times. UBM Medica LLC. Web. Sept [
Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More informationAD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
More information2013 Virtual AD/HD Conference 1
Medication for & Coexisting Conditions Part 2 Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com
More informationHumberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
More informationPharmacologic Management of ADHD
Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine
More informationADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
More informationThe Use of ADHD Medication in the Pediatric Population
The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationParents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
More informationADHD Medications: Basics. David Benhayon MD, PhD
ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationAttention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD
Attention Deficit Hyperactivity Disorder State of the Art Christopher Okiishi, MD What is ADHD? Three subtypes: Inattentive (under diagnosed, esp. in girls) Hyperactive Impulsive Combined Impairments must
More informationBig Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
More informationDose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
More informationADHD Part II: Managing Comorbities
ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have
More informationGA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
More informationBehavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
More informationWhat are the most common signs of ADHD? And what are the most common medication interventions?
What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More information7/9/2013. Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly. What ADHD is
Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly Gabrielle A. Carlson, MD Professor of Psychiatry and Pediatrics Director, Child and Adolescent Psychiatry Stony
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationChange Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness
Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationTreating Disruptive Behavior Disorders in Children and Teens. A Review of the Research for Parents and Caregivers
Treating Disruptive Behavior Disorders in Children and Teens A Review of the Research for Parents and Caregivers e Is This Information Right for Me? This information is for you if: A health care professional*
More informationAsk The Shrink: ADHD
Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More
More informationPsychiatric medication treatment in children and adolescents:
Psychiatric medication treatment in children and adolescents: The good, the bad and the ugly Gabrielle A. Carlson, MD Professor of Psychiatry and Pediatrics Director, Child and Adolescent Psychiatry Stony
More informationCreating Partnerships. Laine Young-Walker, MD
Creating Partnerships Laine Young-Walker, MD Psychiatry is the medical specialty devoted to the study, diagnosis, treatment and prevention of mental disorders. Medical school >>>four years of residency
More informationWe ll Be Discussing. Pregnancy 4/24/2013
Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free monthly e-newsletter? We ll Be Discussing The safety and efficacy track
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationAttention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D.
Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. PREVALENCE & STATISTICS 6-8% of all children have ADHD (CDC Statistical Data) Age of onset: 7 years old (Prior DSM-IV) 12 years old (Current
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationManaging the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center
Managing the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center Abstract: The majority of boys and many girls with fragile X
More informationContents Definition and History of ADHD Causative Factors
1 Definition and History of ADHD................... 1 Brain Damage Syndromes........................ 1 Alternative Terms for ADHD...................... 2 Evolution of Present Concept of ADHD................
More informationOptions for Medication Management: Rx and OTC/Natural Treatments AMY NEWMEYER MD CHKD DIVISION OF DEVELOPMENTAL PEDIATRICS MARCH 24, 2018.
Options for Medication Management: Rx and OTC/Natural Treatments AMY NEWMEYER MD CHKD DIVISION OF DEVELOPMENTAL PEDIATRICS MARCH 24, 2018 Disclosures I have no conflicts of interest to disclose 1 Objectives
More informationChild & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
More informationDrug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
More informationOhio Psychotropic Medication Quality Improvement Collaborative. Minds Matter. Toolkit. for You and Your Family. This is the property of
Minds Matter Ohio Psychotropic Medication Quality Improvement Collaborative Minds Matter Toolkit for You and Your Family This is the property of About Minds Matter Minds Matter is a project to help teens,
More informationMental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling
Mental Illness Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Moodiness Changing Bodies Narcissism Self-Esteem Ignorant Naïve Insecure Self-Centered Independent Adolescence Disorders Affecting
More informationStimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
More informationTo Give or not to Give Medication: That is the Question
To Give or not to Give Medication: That is the Question Charmi Patel Rao, MD September 14, 2018 Introduction Board Certified Child & Adolescent Psychiatrist Clinical expertise in ECMH and Developmental
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationIndividuals with attention-deficit/hyperactivity
National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience
More informationUpdate on the Treatment of ADHD 2019
Update on the Treatment of ADHD 2019 James H. Beard, Jr., M.D, FAAP Developmental-Behavioral Pediatrician Division of Developmental Pediatrics The Rights of ADHD The right diagnosis of ADHD and co morbidities
More informationPresented by the National Resource Center on ADHD
Presented by the National Resource Center on ADHD Timothy E. Wilens, M.D. Massachusetts General Hospital Harvard Medical School Save 25% if you join/rejoin CHADD Use Promo Code: JANA14 If you are currently
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationADHD: Management Update
4/5/17 Conflicts of Interest ADHD: Management Update I have no conflicts to disclose. Jennifer R. Walton, MD, MPH, FAAP April 7, 2017 ADHD: DSM-5 Definition Objectives To briefly review ADHD diagnostic
More information35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
More informationADHD: A Focus On Drug Therapy
ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90
More informationIndividuals with attention-deficit/hyperactivity
3 W H A T W E K N O W Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience chronic problems with inattention and/or
More informationFocusing in on Adult ADHD
Focusing in on Adult ADHD Diagnosis, Psychopharmacology, and Therapeutic Interventions Sharon Praissman Fisher, MS, APRN-A, APRN-PMHNP Balance Point Wellness Disclosures I have no financial/professional
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationFocusing in on Adult ADHD
Focusing in on Adult ADHD Diagnosis, Psychopharmacology, and Therapeutic Interventions Sharon Praissman Fisher, MS, APRN-A, APRN-PMHNP Balance Point Wellness Disclosures I have no financial/professional
More informationMedically Accepted Indications for Pediatric Use of Psychotropic Medications by
Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationTrouble shooting medication adjustment and side effect management in children with ADHD
Trouble shooting medication adjustment and side effect management in children with ADHD Drs. Joanna Holland and Sarah Manos 44 th Annual Dalhousie Spring Refresher April 5, 2018 Disclosure We have no disclosures
More informationADHD Assessment and Treatment in Primary Care
ADHD Assessment and Treatment in Primary Care Matthew Tolliver, Ph.D., Assistant Professor, ETSU Pediatrics Dr. David Wood, Professor and Chair, ETSU Pediatrics ADHD in Teenagers We have no financial disclosures.
More informationEvidence-Based Pharmacotherapy. Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center
Evidence-Based Pharmacotherapy Emily Harris, MD, MPH, FAAP Cincinnati Children s Hospital Medical Center CME Disclosure I have no personal financial relationships in any commercial interest related to
More informationDisclosures. Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1:05-2:20pm ADD & ADHD in Children and Adults: Beyond Stimulants SPEAKER Daniel Press, MD ADD & ADHD in Children and Adults: Beyond Stimulants Daniel Press, M.D. Associate Professor in Neurology Beth Israel
More information23/06/2015. Absolutely none!!
Absolutely none!! Child and adolescent Mental Health can we help? Dr Tina Nicholson CCFP Family Practitioner and Medical Lead, Cochrane Clinical Lecturer Dept Family Med. U of C. Member of CanReach Faculty
More informationADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com
More informationThe Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD
The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD Damon Korb, MD Behavioral and Developmental Pediatrician Director of the Center for Developing Minds Los Gatos,
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationRecognition and Treatment of ADHD in Primary Care Settings. Disclosure 11/6/2013. Objectives
Southern California Permanente Medical Group Pediatric Symposium Hyatt, Long Beach CA. 11/1/13 Recognition and Treatment of ADHD in Primary Care Settings Martin T. Stein, M.D. Professor of Pediatrics Division
More informationADHD and. Shaw Wendi Fortuchang, M.D. Board certified in Child & Adolescent, Adult, and Forensic Psychiatry
ADHD and Beyond Shaw Wendi Fortuchang, M.D. Board certified in Child & Adolescent, Adult, and Forensic Psychiatry Overview Use of medications in children How do medications work in the brain? Risperdal?
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationAttention Deficit Hyperactivity Disorder in Children and Adults
Attention Deficit Hyperactivity Disorder in Children and Adults Steven R. Pliszka, MD Professor and Chair Department of Psychiatry The University of Texas Health Science Center at San Antonio Speaker Disclosure
More information5/2/2017. By Pamela Pepper PMH, CNS, BC. DSM-5 Growth and Development
By Pamela Pepper PMH, CNS, BC DSM-5 Growth and Development The idea that diagnosis is based on subjective criteria and that those criteria should fall neatly into a set of categories is not sustainable,
More informationAmphetamines
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.24 Subject: Amphetamines Page: 1 of 6 Last Review Date: December 8, 2017 Amphetamines Description
More informationADHD Explanation 5: Medications used in ADHD
ADHD Explanation 5: Medications The aim of treatment is efficient functioning and achieving goals in life It is most important to find the dose of medications that works best As children grow they may
More informationOverview of ADHD Symptoms in ID/D
Overview of ADHD Symptoms in ID/D Laura Politte, M.D. Child and Adolescent Psychiatry Carolina Institute for Developmental Disabilities November 8, 2017 Define Define symptoms of ADHD, as defined by DSM-5
More informationA REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE
A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE OVERVIEW Review Stimulant Treatment for ADHD STIMULANTS
More informationADHD in the Preschool Aged Child
ADHD in the Preschool Aged Child (PATS) 11/2/2013 Stephen Meister MD, MHA, FAAP The Edmund N Ervin Pediatric Center (PATS) National Institute of Mental Health study First papers published in 2006 after
More informationOVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationADHD SIV FASCI, MD FAAP DEVELOPMENTAL-BEHAVIORAL PEDIATRICS DELL CHILDREN S MEDICAL CENTER 9TH ANNUAL PEDIATRIC CONFERENCE - MARCH 24, 2016
ADHD SIV FASCI, MD FAAP DEVELOPMENTAL-BEHAVIORAL PEDIATRICS DELL CHILDREN S MEDICAL CENTER 9TH ANNUAL PEDIATRIC CONFERENCE - MARCH 24, 2016 Objectives Epidemiology Risk Factors Diagnosis Co-morbidities
More informationCerebral Stimulant and ADHD Drugs Prior Authorization Request
Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 2009 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationAttention Deficit Hyperactivity Disorder Overview and New Perspectives
1st Annual Regional Psychiatry Conference Psychiatry for the Non-Psychiatrist Attention Deficit Hyperactivity Disorder Overview and New Perspectives Thomas B. Henry, MD Board Certified Child & Adolescent
More informationAmphetamines
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.24 Subject: Amphetamines Page: 1 of 6 Last Review Date: September 23, 2016 Amphetamines Description
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationCommon Psychiatric Conditions in Children. Steven Klamerus, M.D. Child and Adolescent Psychiatrist Marquette General Hospital
Common Psychiatric Conditions in Children Steven Klamerus, M.D. Child and Adolescent Psychiatrist Marquette General Hospital (Child) Psychiatry is different Phenomenological diagnoses verses pathologic
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationModern Day Challenges to ADHD in the Primary Care Setting. Rebecca C. Moore, DO Meagan W. Vermeulen, MD
ACOFP 54 th Annual Convention & Scientific Seminars Modern Day Challenges to ADHD in the Primary Care Setting Rebecca C. Moore, DO Meagan W. Vermeulen, MD Modern Day Challenges to ADHD in the Primary
More information6/2/2011. At the end of the presentation you will be able to: What is Adult Attention Deficit Hyperactivity Disorder?
At the end of the presentation you will be able to: Adult Attention Deficit Hyperactive Disorder (ADHD) Concern for our patients wellbeing. 1. Describe the most common behaviors and problems associated
More informationBeyond the Practice Parameters
Volume 17 l Number 3 l Fall 2010 Attention Deficit Hyperactivity Disorder: Beyond the Practice Parameters By Shelly Flynn, RN, MA, ARNP Division of Pediatric Neurology, Behavior and Development University
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 22 Number 10 October 2016 T Amphetamine Orally Disintegrating Tablets: Another Option for the Treatment of Attention Deficit Hyperactivity Disorder Marcia L. Buck, PharmD,
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationThe Mental Health and Wellbeing of Children and Adolescents who are affected by Autism and Related Disorders
The Mental Health and Wellbeing of Children and Adolescents who are affected by Autism and Related Disorders Charles Cartwright, M.D Director: YAI Autism Center March 2013 Autism Spectrum Defined by the
More informationPsychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.
Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence
More information